Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4475-4482

  Tarhini, Ahmad A ^a   Zahoor, Haris ^a   Mclaughlin, Brian ^a   Gooding, William E ^a   Schmitz, John C ^a   Siegfried, Jill M ^a   Socinski, Mark A ^a   Argiris, Athanassios ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Carboplatin; Etoposide; Lung cancer; Panobinostat

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PANOBINOSTAT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DOSE LIMITING TOXICITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INSOMNIA; LIMB PAIN; LUNG CANCER; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; THROMBOCYTOPENIA; TOXICOLOGICAL PARAMETERS; VOMITING;

CARBOPLATIN; ETOPOSIDE; LUNG CANCER; PANOBINOSTAT;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; EARLY TERMINATION OF CLINICAL TRIALS; ETOPOSIDE; HUMANS; HYDROXAMIC ACIDS; INDOLES; LUNG NEOPLASMS; MIDDLE AGED;

EID: 84891350230     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
3. Carew JS, Giles FJ and Nawrocki ST: Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269: 7-17, 2008.
4. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD and Albelda SM: The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8: 2221-2231, 2009.
5. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA and Schrump DS: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94: 504-513, 2002.
6. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, Porro MG, Woo MM and Lewis LD: The effect of food on the bioavailability of panobinostat, an orally active panhistone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69: 555-562, 2012.
7. Prince HM, Bishton MJ and Johnstone RW: Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5: 601-612, 2009.
8. Gray JE, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder MC, Neuger A, Giglia JL, Bepler G and Altiok S: Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers. J Clin Oncol 28: (suppl; abstr e13016), 2010.
9. Di Meglio G, Massacesi C, Radice D, Boselli S, Pelosi G, Squadroni M, Spada F, Lorizzo K, De Braud FG and Fazio N: Carboplatin with etoposide in patients with extrapulmonary "aggressive" neuroendocrine carcinoma. J Clin Oncol 28: (suppl; abstr e13072), 2010.
10. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J and Gilchrist J: Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18: 2493-2499, 2000.
11. Le Treut JH, Sault M, Chouaid C, Vergnenegre A, Arpin D, Geriniere L, Berard H, Lena H, Paillotin D and Caer HL: Multicentric phase II trial of cisplatin/etoposide chemotherapy in advanced large-cell neuroendocrine carcinoma of the lung (LCNEC): Study GFPC 03-02 from the Groupe Francais de Pneumo-cancerologie. J Clin Oncol 28: (suppl; abstr e18018), 2010.
12. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, Kantarjian H, Dugan M, Albitar M and Bhalla K: A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 12: 4628-4635, 2006.
13. Ivanova A, Montazer-Haghighi A, Mohanty SG and Durham SD: Improved up-and-down designs for phase I trials. Stat Med 22: 69-82, 2003.
14. Atadja P: Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280: 233-241, 2009.
15. Rasheed W, Bishton M, Johnstone RW and Prince HM: Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 8: 413-432, 2008.
16. Lin R, Hu J, Paul S, Schindler J, Woo MW, Spence S, Hirawat S and Weber HA: Characteristics of thrombocytopenia in pateints treated with oral panobinostat (LBH589). Blood 114: (abstract 2740), 2009.
17. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W and Scher HI: A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66: 181-189, 2010.
18. Jones SF, Bendell JC, Infante JR, Spigel DR, Thompson DS, Yardley DA, Greco FA, Murphy PB and Burris HA, 3rd: A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors. Clin Adv Hematol Oncol 9: 225-230, 2011.
19. Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, Masson E, Culver KW, Burris HA, 3rd and Beck J: Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. J Clin Oncol 25: (suppl. abstract 3500), 2007.
20. Alsina M, Lonial S, Weber DM, Coutre SE, Kang BP, Glynos T, Warsi G, Snodgrass SM and Richardson PG: PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). J Clin Oncol 28: (suppl; TPS308), 2010.
21. Deangelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK and Ottmann OG: Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia, 2013.
22. Ottmann OG, DeAngelo DJ, Garcia-Manero G, Lubbert M, Jillella A, Sekeres MA, Zahlten A, Squier M, Acharyya S, Winiger IJ and Fenaux P: Determination of a phase II dose of panobinostat in combination with 5-azacitidine in patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia. Blood 118: (abstract 459), 2011.
23. Richardson PG, Alsina M, Weber D, Coutre SE, Lonial S, Gasparetto C, Mukhopadhyay S, Ondovik M, Khan M, Paley C and Schlossman R: PANORAMA 2: Panobinostat combined with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. Blood 120: (abstract 1852), 2012.
24. Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C and Elias A: Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J Clin Oncol 27: (suppl; abstr 1081), 2009.
25. Rathkopf DE, Chi KN, Vaishampayan U, Hotte S, Vogelzang N, Alumkal J, Agrawal M, Nydam TM, Fandi A and Scher HI: Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 27: (suppl; abstr 5064), 2009.